DE60121136D1 - Proteasom-influenzavirus-impfstoffzusammensetzung - Google Patents

Proteasom-influenzavirus-impfstoffzusammensetzung

Info

Publication number
DE60121136D1
DE60121136D1 DE60121136T DE60121136T DE60121136D1 DE 60121136 D1 DE60121136 D1 DE 60121136D1 DE 60121136 T DE60121136 T DE 60121136T DE 60121136 T DE60121136 T DE 60121136T DE 60121136 D1 DE60121136 D1 DE 60121136D1
Authority
DE
Germany
Prior art keywords
proteasome
influenza virus
vaccine composition
virus vaccine
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60121136T
Other languages
English (en)
Other versions
DE60121136T2 (de
Inventor
S Burt
H Lowell
Lee White
F Fries
Kirkor Torossian
Hugh Jones
Martin Plante
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ID Biomedical Corp of Quebec
Original Assignee
ID Biomedical Corp of Quebec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ID Biomedical Corp of Quebec filed Critical ID Biomedical Corp of Quebec
Application granted granted Critical
Publication of DE60121136D1 publication Critical patent/DE60121136D1/de
Publication of DE60121136T2 publication Critical patent/DE60121136T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
DE60121136T 2000-02-15 2001-02-15 Proteasom-influenzavirus-impfstoffzusammensetzung Expired - Lifetime DE60121136T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18247600P 2000-02-15 2000-02-15
US182476P 2000-02-15
PCT/US2001/005222 WO2001060402A2 (en) 2000-02-15 2001-02-15 Proteosome influenza vaccine

Publications (2)

Publication Number Publication Date
DE60121136D1 true DE60121136D1 (de) 2006-08-10
DE60121136T2 DE60121136T2 (de) 2007-06-06

Family

ID=22668645

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60121136T Expired - Lifetime DE60121136T2 (de) 2000-02-15 2001-02-15 Proteasom-influenzavirus-impfstoffzusammensetzung

Country Status (12)

Country Link
US (3) US6743900B2 (de)
EP (1) EP1255561B1 (de)
JP (2) JP3980884B2 (de)
AT (1) ATE331530T1 (de)
AU (4) AU2001238478C1 (de)
CA (1) CA2400468C (de)
DE (1) DE60121136T2 (de)
ES (1) ES2267724T3 (de)
HK (1) HK1052629A1 (de)
IL (2) IL150602A0 (de)
NO (1) NO20023829L (de)
WO (1) WO2001060402A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL123720A (en) * 1995-09-18 2002-02-10 Us Army Medical Res Material C Methods for the creation of immune subunits of proteasomes that are multivolent and non-covalently linked
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
DE60121136T2 (de) * 2000-02-15 2007-06-06 Id Biomedical Corporation Of Quebec, Ville St. Laurent Proteasom-influenzavirus-impfstoffzusammensetzung
EP1372706B1 (de) * 2001-03-09 2010-12-01 ID Biomedical Corporation of Quebec Proteosom-liposaccharid-vakzine-adjuvans
BR0214279A (pt) 2001-11-19 2005-12-20 Becton Dickinson Co Composições farmacêuticas em forma particulada
RU2378008C2 (ru) * 2002-05-14 2010-01-10 Новартис Вэксинес Энд Дайэгностикс С.Р.Л. Комбинированные вакцины против бактериального менингита для введения через слизистую оболочку
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
AU2003296592A1 (en) * 2002-11-20 2004-06-15 Crucell Holland B.V. Antigen-complexes
EP1447080A1 (de) 2003-02-13 2004-08-18 Bestewil Holding B.V. Methode zur Herstellung von Virosomen-artigen Partikeln
AR056245A1 (es) * 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
EP1667713A1 (de) * 2003-09-15 2006-06-14 ID Biomedical Corporation of Quebec Masern-untereinheit-vakzine
GB0323231D0 (en) * 2003-10-03 2003-11-05 Chiron Srl Immunodiffusion assays
WO2005042017A1 (en) 2003-10-22 2005-05-12 Id Biomedical Corporation Of Quebec Compositions and methods for activating innate and allergic immunity
CN101039691B (zh) * 2004-06-25 2013-07-31 魁北克益得生物医学公司 用于治疗神经疾病的组合物和方法
KR20070052273A (ko) * 2004-06-30 2007-05-21 아이디 바이오메디컬 코포레이션 오브 퀘벡 코로나바이러스 감염의 치료를 위한 백신 조성물
CA2610245A1 (en) * 2005-06-02 2006-12-07 Alza Corporation Method for terminal sterilization of transdermal delivery devices
US20080038294A1 (en) * 2006-03-22 2008-02-14 Kersten Alexander J Intranasal or inhalational administration of virosomes
US8535683B2 (en) * 2006-03-22 2013-09-17 Abbott Biologicals B.V. Intranasal or inhalational administration of virosomes
WO2008073490A1 (en) * 2006-12-12 2008-06-19 Carrington Laboratories Inc., Purification of influenza viral antigens
MX2009009912A (es) 2007-03-27 2010-01-18 Sea Lane Biotechnologies Llc Constructos y colecciones que comprenden secuencias de cadena ligera sustitutas de anticuerpos.
EP2268309B1 (de) * 2008-03-18 2015-01-21 Novartis AG Verbesserungen der herstellung von grippevirus-impstoff-antigenen
AU2009228058A1 (en) * 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
KR100966566B1 (ko) 2009-01-29 2010-06-29 엘지전자 주식회사 효율적인 공용 ｅ-ｄｃｈ 관리를 위한 신호 전송 기법
WO2010132604A2 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
US9757448B2 (en) 2010-02-26 2017-09-12 The Brigham And Women's Hospital, Inc. Methods of treating cerebral amyloid angiopathy
CN104203275A (zh) 2010-06-09 2014-12-10 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
CA2862871C (en) 2011-01-13 2020-09-22 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
WO2013016714A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3
CA2890084C (en) 2011-11-18 2021-05-04 Maura Ellen Campbell Synthetic derivatives of mpl and uses thereof
EP2793940B1 (de) 2011-12-22 2018-11-14 i2 Pharmaceuticals, Inc. Surrogatbindungsproteine
EP2802353A4 (de) 2012-01-12 2015-12-02 Variation Biotechnologies Inc Zusammensetzungen und verfahren zur behandlung von virusinfektionen
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
KR101601393B1 (ko) 2014-02-20 2016-03-09 현대자동차주식회사 차량용 비상 버튼
WO2018128688A1 (en) 2016-11-04 2018-07-12 Baxalta Incorporated Adeno-associated virus purification methods
WO2019035972A1 (en) * 2017-08-16 2019-02-21 Georgia State University Research Foundation, Inc. SEQUENTIAL IMMUNIZATIONS WITH HIV-1 ENV VIRUS TYPE PARTICLES
EP4277654A1 (de) 2021-01-18 2023-11-22 Conserv Bioscience Limited Immunogene coronavirus-zusammensetzungen, verfahren und verwendungen davon

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
DE3830496C1 (de) * 1988-09-08 1996-09-19 Daimler Benz Aerospace Ag Vorrichtung zum Erkennen und Verfolgen von Objekten
SK279209B6 (sk) * 1992-12-21 1998-08-05 Virologický Ústav Sav Bivalentné imunogény a spôsob ich prípravy
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
IL123720A (en) 1995-09-18 2002-02-10 Us Army Medical Res Material C Methods for the creation of immune subunits of proteasomes that are multivolent and non-covalently linked
ES1032221Y (es) * 1995-10-04 1996-11-01 Ferre Jose Manuel Rodriguez Tobogan componible perfeccionado para uso infantil.
CA2259961A1 (en) * 1996-07-10 1998-01-15 Intellivax, Inc. Protein and peptide vaccines for inducing mucosal immunity
JP3426177B2 (ja) * 1999-12-28 2003-07-14 明智セラミックス株式会社 鋳造用ストッパー
DE60121136T2 (de) * 2000-02-15 2007-06-06 Id Biomedical Corporation Of Quebec, Ville St. Laurent Proteasom-influenzavirus-impfstoffzusammensetzung
US6726292B1 (en) * 2000-07-27 2004-04-27 Daimlerchrysler Corporation Full off-set two-piece fiber reinforced composite wheel using spoke or web area box sections

Also Published As

Publication number Publication date
NO20023829D0 (no) 2002-08-13
CA2400468A1 (en) 2001-08-23
AU2009201657A1 (en) 2009-05-21
IL150602A0 (en) 2003-02-12
EP1255561B1 (de) 2006-06-28
DE60121136T2 (de) 2007-06-06
IL150602A (en) 2010-12-30
JP3980884B2 (ja) 2007-09-26
JP2003522802A (ja) 2003-07-29
AU2006202003A1 (en) 2006-06-01
US6743900B2 (en) 2004-06-01
JP2007051157A (ja) 2007-03-01
EP1255561A2 (de) 2002-11-13
US20080260781A1 (en) 2008-10-23
WO2001060402A2 (en) 2001-08-23
US20040156867A1 (en) 2004-08-12
ES2267724T3 (es) 2007-03-16
AU3847801A (en) 2001-08-27
ATE331530T1 (de) 2006-07-15
WO2001060402A3 (en) 2002-03-21
US20010053368A1 (en) 2001-12-20
US7399840B2 (en) 2008-07-15
NO20023829L (no) 2002-08-13
CA2400468C (en) 2012-12-18
AU2001238478C1 (en) 2006-11-09
HK1052629A1 (en) 2003-09-26
AU2001238478B2 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
DE60039198D1 (de) Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
FR2814958B1 (fr) Composition vaccinale
CY1110585T1 (el) ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ
AR014182A1 (es) Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones
ATE491467T1 (de) Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
MY126588A (en) Intranasal influenza virus vaccine
DE60144240D1 (de) Zusammensetzung mit immunogenen mikroteilchen
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
DE60335186D1 (de) Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
AU2003246373A1 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
EA200801251A1 (ru) Вакцины против гриппа, адсорбированные на алюминиевых адъювантах, для немедленного приёма
ATE511855T1 (de) Adjuvansformulierung zur scheimhaut-applikation
UY26882A1 (es) Nuevo tratamiento
BR0010711A (pt) Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
EP1721618A3 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
WO2002036160A3 (es) Método de obtención de estructuras antigénicas que potencian la reactividad cruzada específica
AR034771A1 (es) Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
AR020852A1 (es) Antigenos de vacuna de leptospira para la prevencion de leptospirosis
AR037908A1 (es) Una biomasa en particulas de embrion aviar para la produccion de antigenos de virus
DK1490100T3 (da) Kombinerede DNA/proteinvaccinepræparater
WO2002072622A3 (en) Vaccine antigens against infection by chlamydia trachomatis
TH88608B (th) สารผสมทางเภสัชกรรมซึ่งสามารถชักนำให้เกิดการตอบสนองเชิงปกป้องของภูมิคุ้มกันต้านไวรัส Dengue ซึ่งมีโปรตีนห่อหุ้มไวรัส Dengue

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ID BIOMEDICAL CORPORATION OF QUEBEC, LAVAL, QU, CA

8364 No opposition during term of opposition